Clinical Trials
313
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (202 trials with phase data)• Click on a phase to view related trials
Artificial Intelligence Used in Screening Adrenal Nodules
- Conditions
- Adrenal IncidentalomasThoracic CT-scan
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT07198152
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors
- Conditions
- Primary AldosteronismAdrenal TumorCushing s SyndromePheochromocytoma/Paraganglioma (PPGL)
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT07182175
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
Construction and Validation of a Predictive Model for the Efficacy of Different Biologics in Inflammatory Bowel Disease
- Conditions
- Inflamatory Bowel Disease
- Interventions
- Drug: anti-cytokine antibodiesDrug: anti-integrin antibodies
- First Posted Date
- 2025-09-18
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT07181525
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT
- Conditions
- Carcinoma, Renal CellDiagnostic ImagingPathologyDeep Learning
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT07166445
- Locations
- 🇨🇳
Peking University First Hospital, Beijing,, Beijing, China
Development, Application, and Mechanistic Investigation of a Novel Minimally-Invasive Bidirectional Epidural Cerebellar Stimulation Technique for Cerebellar Cognitive Affective Syndrome
- Conditions
- Cerebellar AtrophyPhysiopathologyEtiology
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT07166432
- Locations
- 🇨🇳
Department of Urology, Peking University First Hospital, Beijing, 100034, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 61
- Next
News
Cellular Senescence Gene Signature Reveals New Biomarkers for Idiopathic Pulmonary Fibrosis
Researchers identified four key cellular senescence-related genes (CDKN2A, VEGFA, SOX2, and FOXO3) that could serve as diagnostic biomarkers for idiopathic pulmonary fibrosis (IPF).
Everest Medicines Reports Promising Phase 1b/2a Results for EVER001 BTK Inhibitor in Primary Membranous Nephropathy
Everest Medicines presented positive Phase 1b/2a trial results for EVER001, a next-generation covalent reversible BTK inhibitor, showing significant efficacy in treating primary membranous nephropathy at the 62nd European Renal Association Congress.
Meta-Analysis Confirms Efficacy of Traditional Chinese Medicine Si-Shen-Wan for Treating IBS-D
A comprehensive meta-analysis of 34 randomized controlled trials involving 2,976 participants has validated the efficacy of Si-Shen-Wan (SSW) in treating diarrhea-predominant irritable bowel syndrome.
VivaVision's VVN461 Shows Promising Results in Phase 2 Trial for Non-Infectious Anterior Uveitis
VivaVision Biotech's dual JAK1/TYK2 inhibitor VVN461 demonstrated non-inferior efficacy to prednisolone acetate in treating non-infectious anterior uveitis in a Phase 2 trial conducted across 10 clinical sites in China.